Third-Line Treatment Timing After Second-Line Discontinuation in Advanced Pancreatic Cancer: A 30-Day Landmark...

Area of Science:

• Oncology
• Clinical Cancer Research
• Gastrointestinal Oncology

Background:

• Limited evidence exists for third-line systemic therapy in advanced pancreatic cancer.
• Observational studies comparing treatments risk significant time-related and selection biases.

Purpose of the Study:

• To evaluate the impact of third-line systemic therapy initiation timing after second-line discontinuation in advanced pancreatic cancer.
• To address biases by using a 30-day landmark strategy focusing on patient selection and treatment timing.

Main Methods:

• Retrospective cohort study of advanced pancreatic cancer patients discontinuing second-line therapy.
• Primary analysis used a 30-day landmark for patients with ECOG PS 0-1 alive at day 30.
• Compared overall survival (OS) for early (within 30 days) versus delayed/no initiation, with sensitivity analyses including a 45-day landmark and overlap weighting.

Main Results:

• Early third-line initiation demonstrated a directionally favorable but imprecise association with improved OS (aHR 0.40) at the 30-day landmark.
• Similar trends were observed at the 45-day landmark (aHR 0.33), though attenuated with overlap weighting (aHR 0.68).
• Sixty-day mortality post-initiation was 18.9%, associated with ECOG PS ≥2.

Conclusions:

• Early third-line therapy initiation in selected advanced pancreatic cancer patients (ECOG PS 0-1, alive at day 30) showed a trend towards better OS.
• The findings support time-bound patient selection and integrated decision-making, rather than definitive causal inference.
• Results highlight the importance of timely treatment decisions and supportive care in this patient population.